Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial

Background: Diarrhoea-predominant irritable bowel syndrome (IBS-D) is a common outcome after inflammation due to bacterial gastroenteritis. Several studies have shown ongoing immune activation in the mucosa of patients with IBS-D and a number of studies have suggested that mesalazine slow-release gr...

Full description

Bibliographic Details
Main Authors: Ching Lam, Wei Tan, Matthew Leighton, Margaret Hastings, Melanie Lingaya, Yirga Falcone, Xiaoying Zhou, Luting Xu, Peter Whorwell, Andrew F Walls, Abed Zaitoun, Alan Montgomery, Robin C Spiller
Format: Article
Language:English
Published: NIHR Journals Library 2015-03-01
Series:Efficacy and Mechanism Evaluation
Subjects:
efficacy
action
mesalazine
treatment
diarrhoea
irritable bowel syndrome
a multicentre randomised controlled trial
placebo
Online Access:https://doi.org/10.3310/eme02020

Internet

https://doi.org/10.3310/eme02020

Similar Items